微小 RNA 作为肾病综合征的生物标志物。
MicroRNAs as Biomarkers for Nephrotic Syndrome.
机构信息
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
出版信息
Int J Mol Sci. 2020 Dec 23;22(1):88. doi: 10.3390/ijms22010088.
Abstract
Nephrotic syndrome represents the clinical situation characterized by presence of massive proteinuria and low serum protein caused by a variety of diseases, including minimal change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS) and membranous glomerulonephropathy. Differentiating between diagnoses requires invasive renal biopsies in general. Even with the biopsy, we encounter difficulties to differentiate MCNS and FSGS in some cases. There is no other better option currently available for the diagnosis other than renal biopsy. MicroRNAs (miRNAs) are no-coding RNAs of approximately 20 nucleotides in length, which regulate target genes in the post-transcriptional processes and have essential roles in many diseases. MiRNAs in serum and urine have been shown as non-invasive biomarkers in multiple diseases, including renal diseases. In this article, we summarize the current knowledge of miRNAs as the promising biomarkers for nephrotic syndrome.
摘要
肾病综合征代表了一种临床情况，其特征是大量蛋白尿和血清蛋白降低，由多种疾病引起，包括微小病变肾病综合征（MCNS）、局灶节段性肾小球硬化（FSGS）和膜性肾小球肾炎。一般来说，区分这些诊断需要进行有创性的肾活检。即使进行了活检，在某些情况下，我们仍然难以区分 MCNS 和 FSGS。目前，除了肾活检之外，没有其他更好的诊断方法。微 RNA（miRNA）是长度约为 20 个核苷酸的非编码 RNA，在转录后过程中调节靶基因，并在许多疾病中发挥重要作用。血清和尿液中的 miRNA 已被证明是多种疾病（包括肾脏疾病）的非侵入性生物标志物。本文总结了 miRNA 作为肾病综合征有前途的生物标志物的最新知识。
相似文献
1
MicroRNAs as Biomarkers for Nephrotic Syndrome.微小 RNA 作为肾病综合征的生物标志物。
Int J Mol Sci. 2020 Dec 23;22(1):88. doi: 10.3390/ijms22010088.
2
3
Distribution of pathologic findings in individuals with nephrotic proteinuria according to serum albumin.根据血清白蛋白水平，肾病性蛋白尿患者的病理结果分布情况。
Nephrol Dial Transplant. 2008 May;23(5):1595-9. doi: 10.1093/ndt/gfm833. Epub 2007 Dec 8.
4
Proteomic profile‑based screening of potential protein biomarkers in the urine of patients with nephrotic syndrome.基于蛋白质组学谱的肾病综合征患者尿液中潜在蛋白生物标志物的筛选。
Mol Med Rep. 2017 Nov;16(5):6276-6284. doi: 10.3892/mmr.2017.7329. Epub 2017 Aug 22.
5
Histopathological diagnosis and outcome of paediatric nephrotic syndrome.儿童肾病综合征的组织病理学诊断与预后
J Coll Physicians Surg Pak. 2004 Apr;14(4):229-33.
6
Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome.特发性肾病综合征患儿外周血单个核细胞中Toll样受体3（TLR-3）、TLR-4及CD80的表达以及尿CD80水平
Pediatr Nephrol. 2017 Aug;32(8):1355-1361. doi: 10.1007/s00467-017-3613-8. Epub 2017 Feb 16.
7
Plasma microRNA-186 and proteinuria in focal segmental glomerulosclerosis.局灶节段性肾小球硬化症中的血浆 microRNA-186 和蛋白尿。
Am J Kidney Dis. 2015 Feb;65(2):223-32. doi: 10.1053/j.ajkd.2014.07.013. Epub 2014 Sep 11.
8
Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations.胆固醇动脉粥样硬化栓塞所致肾病综合征相关的局灶节段性肾小球硬化：临床病理相关性
Am J Kidney Dis. 1997 Mar;29(3):334-44. doi: 10.1016/s0272-6386(97)90193-1.
9
The differential diagnostic value of urinary enzyme and amino acid excretion in children with nephrotic syndrome.尿酶及氨基酸排泄在儿童肾病综合征中的鉴别诊断价值
Pediatr Nephrol. 1994 Apr;8(2):142-7. doi: 10.1007/BF00865461.
10
Pathophysiology of minimal change nephrotic syndrome and focal segmental glomerulosclerosis.微小病变型肾病综合征和局灶节段性肾小球硬化症的病理生理学
Nephrology (Carlton). 2007 Dec;12 Suppl 3:S11-4. doi: 10.1111/j.1440-1797.2007.00875.x.
引用本文的文献
1
Recent Advances in miRNA Biomarkers for Diagnosis and Prognosis of Focal Segmental Glomerulosclerosis.微小RNA生物标志物在局灶节段性肾小球硬化诊断和预后中的最新进展
Kidney Dis (Basel). 2025 Apr 7;11(1):283-291. doi: 10.1159/000545240. eCollection 2025 Jan-Dec.
2
Deciphering the urinary microRNAs landscape in nephrotic syndrome: implications as prognostic marker-a non-invasive study.解读肾病综合征患者尿液中的微小RNA图谱：作为预后标志物的意义——一项非侵入性研究
Int Urol Nephrol. 2025 May 6. doi: 10.1007/s11255-025-04546-7.
3
MicroRNA Expression and Target Prediction in Children with Nephrotic Syndrome.儿童肾病综合征中的微小RNA表达及靶标预测
Indian J Nephrol. 2025 Jan-Feb;35(1):59-63. doi: 10.25259/ijn_47_23. Epub 2024 Jun 17.
4
MicroRNAs in idiopathic childhood nephrotic syndrome.儿童特发性肾病综合征中的微小RNA
Clin Exp Nephrol. 2025 Apr;29(4):477-484. doi: 10.1007/s10157-024-02595-3. Epub 2024 Dec 4.
5
Nephrotic Syndrome: A Review.肾病综合征综述
Cureus. 2024 Feb 9;16(2):e53923. doi: 10.7759/cureus.53923. eCollection 2024 Feb.
6
Urinary SPP1 has potential as a non-invasive diagnostic marker for focal segmental glomerulosclerosis.尿 SPP1 可能成为局灶节段性肾小球硬化症的一种非侵入性诊断标志物。
FEBS Open Bio. 2023 Nov;13(11):2061-2080. doi: 10.1002/2211-5463.13704. Epub 2023 Sep 27.
7
Exploration of the possible mechanisms of Ling Gui Zhu Gan decoction in nephrotic syndrome based on network pharmacology, molecular docking and molecular dynamics simulation.基于网络药理学、分子对接和分子动力学模拟探究苓桂术甘汤治疗肾病综合征的可能作用机制。
Medicine (Baltimore). 2023 Jul 21;102(29):e34446. doi: 10.1097/MD.0000000000034446.
8
Sanqi Qushi Granule Alleviates Proteinuria and Podocyte Damage in NS Rat: A Network Pharmacology Study and in vivo Experimental Validation.三七祛湿颗粒减轻 NS 大鼠蛋白尿及足细胞损伤：网络药理学研究及体内实验验证。
Drug Des Devel Ther. 2023 Jun 19;17:1847-1861. doi: 10.2147/DDDT.S403617. eCollection 2023.
9
Defining diagnostic trajectories in patients with podocytopathies.定义足细胞病患者的诊断轨迹。
Clin Kidney J. 2022 May 3;15(11):2006-2019. doi: 10.1093/ckj/sfac123. eCollection 2022 Nov.
10
Experimental Study on the Mechanism of Cinnamaldehyde Ameliorate Proteinuria Induced by Adriamycin.肉桂醛改善阿霉素诱导蛋白尿机制的实验研究。
Biomed Res Int. 2022 Jul 23;2022:9600450. doi: 10.1155/2022/9600450. eCollection 2022.
本文引用的文献
1
MicroRNA in Gastric Cancer Development: Mechanisms and Biomarkers.微小RNA在胃癌发生发展中的作用机制及生物标志物
Diagnostics (Basel). 2020 Oct 31;10(11):891. doi: 10.3390/diagnostics10110891.
2
MicroRNA Biomarkers in IBD-Differential Diagnosis and Prediction of Colitis-Associated Cancer.炎症性肠病（IBD）的生物标志物诊断和预测与结肠炎相关的癌症。
Int J Mol Sci. 2020 Oct 24;21(21):7893. doi: 10.3390/ijms21217893.
3
Glucocorticoid receptors and their upstream epigenetic regulators in adults with steroid-resistant nephrotic syndrome.糖皮质激素受体及其在类固醇抵抗性肾病综合征成人患者中的上游表观遗传调控因子。
Biofactors. 2020 Nov;46(6):995-1005. doi: 10.1002/biof.1680. Epub 2020 Oct 8.
4
MicroRNAs as Biomarkers and Therapeutic Targets in Inflammation- and Ischemia-Reperfusion-Related Acute Renal Injury.微小 RNA 作为炎症和缺血再灌注相关急性肾损伤的生物标志物和治疗靶点。
Int J Mol Sci. 2020 Sep 14;21(18):6738. doi: 10.3390/ijms21186738.
5
[Role of microRNA-17-5p in the pathogenesis of pediatric nephrotic syndrome and related mechanisms].[微小RNA-17-5p在小儿肾病综合征发病机制中的作用及相关机制]
Zhongguo Dang Dai Er Ke Za Zhi. 2020 Sep;22(9):958-963. doi: 10.7499/j.issn.1008-8830.2003329.
6
Expression Levels of miR-30c and miR-186 in Adult Patients with Membranous Glomerulonephritis and Focal Segmental Glomerulosclerosis.成年膜性肾小球肾炎和局灶节段性肾小球硬化症患者中miR-30c和miR-186的表达水平
Int J Nephrol Renovasc Dis. 2020 Aug 10;13:193-201. doi: 10.2147/IJNRD.S258624. eCollection 2020.
7
ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer.血管生成素样蛋白4（ANGPTL4）过表达与乳腺癌的进展及不良预后相关。
Oncol Lett. 2020 Sep;20(3):2499-2505. doi: 10.3892/ol.2020.11768. Epub 2020 Jun 24.
8
Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury.Semaphorin3A 抑制剂可改善多柔比星诱导的足细胞损伤。
Int J Mol Sci. 2020 Jun 8;21(11):4099. doi: 10.3390/ijms21114099.
9
MiRNAs as potential biomarker of kidney diseases: A review.miRNAs 作为肾脏疾病的潜在生物标志物：综述。
Cell Biochem Funct. 2020 Dec;38(8):990-1005. doi: 10.1002/cbf.3555. Epub 2020 Jun 4.
10
Immunomodulatory and Regenerative Effects of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Renal Diseases.间充质干细胞衍生的细胞外囊泡在肾脏疾病中的免疫调节和再生作用。
Int J Mol Sci. 2020 Jan 23;21(3):756. doi: 10.3390/ijms21030756.
Zotero 插件